Clinical Trials

  • Principal Investigator:

    Richard P. Mayeux, MD, MSc
    The goal of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. We are looking for families and/or individuals (affected or unaffected) of any ethnic background with a family history of Alzheimer's disease and willing to participate.
  • Principal Investigator:

    James M. Noble, MD, MS
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    James M. Noble, MD, MS
    For more than 30 years, The Columbia University Alzheimer's Disease Research Center (ADRC) has worked with thousands of participants who have helped provide important insights into how the brain ages and why Alzheimer's disease may develop. We are actively recruiting adults 65 years of age and older who share our commitment to be part of this nationwide study. Younger participants are welcome if there is a personal or family history of memory loss. Participants, both with and without memory problems, will be comprehensively evaluated beginning with a physician taking a history and performing...
  • Principal Investigator:

    James M. Noble, MD, MS
    Funded by a multi-year research grant from the National Institute on Aging, the DIAN ObservationalStudy enrolls family members who have parents with a mutated gene known to cause dominantly inherited Alzheimer's (DIAD). Through the study, researchers follow individuals and family members to see if insights gained could lead to better understanding of how the disease progresses in order to identify solutions to prevent DIAD or minimize its impact.
  • Principal Investigator:

    Edward Denmead Huey, MD
    The purpose of this study is to determine whether different genes are related to the amount of immune cell activity that occurs in the brain in patients with Alzheimer's disease. Participation in this study involves memory testing, a blood draw, MRI, and two PET scans. The second PET scan will involve putting a catheter in your wrist to draw blood during the scan. You will be compensated $500. After one year, we will invite you back to repeat some tests.
  • Principal Investigator:

    Thomas H. Brannagan III, MD
    The main goal of this study is to look at the effect and safety of efgartigimod PH20 SC in people with chronic inflammatory demyelinating polyneuropathy (CIDP). Another goal of the study is to collect information on how well efgartigimod works, how the body processes efgartigimod, what efgartigimod does to the body, and how your immune system reacts to efgartigimod. This trial will be conducted in 2 stages: An open-label Stage A and a randomized-withdrawal, double-blind, placebo-controlled Stage B. Approximately 360 patients aged 18 years and older male and non-pregnant female are planned to...
  • Principal Investigator:

    Rebecca Straus Farber, MD
    The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on ocrelizumab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after the lastOcrelizumab (OCR) dose, prior to beginning DRF. Baseline visits for individuals remaining on OCR will take place prior to OCR dose. Visits will occur every 6 months for 24 months (total of 5 study visits). Visits will include blood draw as well as clinical assessments.
  • Principal Investigator:

    Fabio M. Iwamoto, MD
    In this research study, we are looking to see how safe and effective the combination of pembrolizumab, ibrutinib and rituximab is in your type of cancer. The FDA (the U.S. Food and Drug Administration) has not approved pembrolizumab, ibrutinib or rituximab for your specific disease but these have been approved for other uses including other types of non-Hodgkins lymphoma.
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.
  • Principal Investigator:

    Andrew B. Lassman, MD
    The purpose of this study is to test the safety of a new vaccine, VBI-1901, and to know more about its ability to boost the response of the immune system against Cytomegalovirus. The reason for testing this vaccine in people with a brain tumor is that it might one day be used to boost the ability of the immune system to fight a certain type of brain tumor. This type of treatment for brain tumors is called immunotherapy.